ORAVERSE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORAVERSE (ORAVERSE).
Oraverse (phentolamine mesylate) is a nonselective alpha-adrenergic antagonist that reverses local anesthesia by vasodilation and increased local blood flow, accelerating the clearance of local anesthetics from the injection site.
| Metabolism | Phentolamine is metabolized primarily by the liver via glucuronidation and sulfate conjugation. The enzymes involved are not fully characterized but likely include UDP-glucuronosyltransferases (UGTs) and sulfotransferases (SULTs). |
| Excretion | Primarily renal excretion of unchanged drug (70-80%), with approximately 15-20% excreted in feces via biliary elimination. Less than 5% undergoes hepatic metabolism. Renal clearance accounts for the majority of total body clearance, and dose adjustment is necessary in patients with creatinine clearance < 30 mL/min. |
| Half-life | Terminal elimination half-life is 3 to 5 hours in healthy adults. In elderly patients or those with renal impairment (CrCl < 30 mL/min), half-life may be prolonged up to 12-15 hours, requiring dose adjustment. The short half-life supports multiple daily dosing in acute settings. |
| Protein binding | Approximately 98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. The high binding limits free fraction, and displacement interactions may occur with other highly bound drugs. |
| Volume of Distribution | Volume of distribution is 0.8 to 1.2 L/kg, indicating extensive distribution into tissues. The large Vd suggests sequestration in peripheral compartments (e.g., fat, muscle), which contributes to the prolonged terminal half-life relative to initial distribution phase. Gender and age do not significantly affect Vd. |
| Bioavailability | Oral bioavailability is 60-70% due to first-pass metabolism in the liver and gut wall. Sublingual bioavailability is approximately 80% due to avoidance of first-pass effect. Intramuscular bioavailability is near 100%. Intravenous administration yields 100% bioavailability. |
| Onset of Action | Oral: Onset of action occurs within 15-30 minutes after administration. Intravenous: Onset is immediate (within 1-2 minutes) after bolus injection. Intramuscular: Onset in 5-10 minutes. Sublingual: Onset in 5-15 minutes. |
| Duration of Action | Duration of clinical effect is 4 to 6 hours for standard doses. Higher doses may prolong duration to 8 hours. The duration correlates with plasma concentration above the minimum effective concentration. Tachyphylaxis may occur with repeated use. In patients with hepatic impairment, duration may be extended. |
| Molecular Weight | 410.5 |
8-12 mg orally once daily.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min). Not recommended in severe renal impairment (eGFR <30 mL/min) due to lack of data. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 6 mg once daily. Child-Pugh Class C: Not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients; no dosing recommendations available. |
| Geriatric use | No specific dose adjustment required, but monitor renal function and for adverse effects such as confusion and falls. |
| 1st trimester | Not recommended; known teratogenicity in animal studies and limited human data. |
| 2nd trimester | Avoid use; risk of fetal growth restriction and oligohydramnios. |
| 3rd trimester | Avoid use; risk of neonatal complications including renal dysfunction and hypotension. |
Clinical note
Comprehensive clinical and safety monograph for ORAVERSE (ORAVERSE).
| Placental transfer | Crosses placenta; detected in fetal plasma with cord-to-maternal ratio ~0.5. |
| Breastfeeding | Excreted in human milk; potential for infant exposure. Use with caution, monitor infant for adverse effects. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to the drug or any excipientsAortic or peripheral artery aneurysmSevere renal impairment (CrCl <30 mL/min)Severe hepatic impairment
| Precautions | Cardiovascular events: May cause transient tachycardia, cardiac arrhythmias, or hypotension; use with caution in patients with cardiovascular disease, arrhythmias, or hypotension., Hypersensitivity: Allergic reactions including urticaria, dyspnea, and angioedema reported., Injection site reactions: Pain, swelling, or paresthesia may occur., Use in children: Safety and efficacy established for ages 6 and older; not studied in children under 6., Drug interactions: Avoid concomitant use with other alpha-adrenergic antagonists or drugs that may cause hypotension., Pregnancy: Category C; use only if potential benefit outweighs risk. |
| Food/Dietary | No significant food interactions. Avoid hot liquids until oral numbness resolves to prevent burns. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | Oraverse (fentanyl) is not indicated for chronic use; however, fentanyl is a pregnancy Category C drug. First trimester: No adequate human studies; animal studies show increased fetal resorptions and developmental delays. Second/third trimester: Risk of neonatal opioid withdrawal syndrome (NOWS) with prolonged use; may cause fetal distress if used during labor. |
| Fetal Monitoring | Monitor maternal respiratory rate, sedation, and oxygen saturation. Fetal heart rate monitoring during labor. Assess newborn for respiratory depression and withdrawal symptoms. |
| Fertility Effects | Animal studies show reduced fertility in females; no human data. Fentanyl may impair male fertility via hormonal disruption (hypothalamic-pituitary-gonadal axis). |
| Clinical Pearls | Oraverse (phentolamine mesylate) is a local anesthetic reversal agent. Administer after dental procedure to reduce soft tissue anesthesia duration. Use 1:1 ratio with anesthetic volume. Contraindicated in patients with sulfite allergy. Monitor for transient bradycardia or hypotension. |
| Patient Advice | You may experience temporary numbness or tingling at the injection site. · Avoid chewing gum or hot foods until normal sensation returns. · Report any chest pain, irregular heartbeat, or severe dizziness immediately. · This medication reverses the numbing effect within 30-60 minutes. |